

COPY OF PAPERS
ORIGINALLY FILED

JO 300
#7

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J.C. Hunt, *et al.*

Serial No.: 10/086,409

Filed: November 19, 2001

For: MOUSE MONOCLONAL ANTIBODY
(5-21-3) TO HUMAN
IMMUNODEFICIENCY VIRUS GP41
PROTEIN

Attorney Docket No.: 4573.US.C6

Examiner: Not Yet Assigned

Group Art Unit: 1642

Certificate of Mailing under 37 CFR §1.8(a):
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on July 25, 2002

Name of person signing
this certificate: Kimberly A. Iorio

Signature: Kimberly A. Iorio

TRANSMITTAL

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN are the following:

1. Preliminary Amendment and Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (5 Pages)
2. Attachment A (4 Pages)
3. Copy of Notice to Comply (2 Pages)
4. Paper Copy of Sequence Listing (3 Pages)
5. Computer Readable Form Copy of Sequence Listing (1 Diskette)
6. Statement to Support Filings and Submissions (1 Page)
7. Return Receipt Postcard


The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-3137
Facsimile: (847) 938-2623

Respectfully submitted,
J.C. Hunt *et al.*


Dianne Casuto
Registration No. 40,943
Attorney for Applicants

08/22/2002 YGIZAW 00000008 010025 10086409

01 FC:116 400.00 CH

DISK TO STIC
JUL 30 2002
PATENT & TRADEMARK OFFICE
DATE: July 30, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/086,409	11/19/2000	Jeffrey C. Hunt	4573.US.C6



Cheryl L. Becker
Abbott Laboratories
D-377, AP6D
100 Abbott Park Road
Abbott Park, IL 60064

COPY OF PAPERS
ORIGINALLY FILED

CONFIRMATION NO. 7509
FORMALITIES LETTER



OC0000000007888709

Date Mailed: 04/17/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Johns

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY